Crystallization and structural analysis are reported of the Rel stringent factor from Thermus thermophilus in the resting state and bound to nucleotides.
Keywords: stringent response, Rel/RelA/SpoT, (p)ppGpp, bacterial alarmone, Thermus thermophilus
Abstract
The stringent response, controlled by (p)ppGpp, enables bacteria to trigger a strong phenotypic resetting that is crucial to cope with adverse environmental changes and is required for stress survival and virulence. In the bacterial cell, (p)ppGpp levels are regulated by the concerted opposing activities of RSH (RelA/SpoT homologue) enzymes that can transfer a pyrophosphate group of ATP to the 3′ position of GDP (or GTP) or remove the 3′ pyrophosphate moiety from (p)ppGpp. Bifunctional Rel enzymes are notoriously difficult to crystallize owing to poor stability and a propensity for aggregation, usually leading to a loss of biological activity after purification. Here, the production, biochemical analysis and crystallization of the bifunctional catalytic region of the Rel stringent factor from Thermus thermophilus (RelTt NTD) in the resting state and bound to nucleotides are described. RelTt and RelTt NTD are monomers in solution that are stabilized by the binding of Mn2+ and mellitic acid. RelTt NTD crystallizes in space group P4122, with unit-cell parameters a = b = 88.4, c = 182.7 Å, at 4°C and in space group P41212, with unit-cell parameters a = b = 105.7, c = 241.4 Å, at 20°C.
1. Introduction
Nutrient starvation in bacteria is signalled by the alarmone guanosine polyphosphate [guanosine 3′,5′-bisdiphosphate and guanosine 5′-triphosphate-3′-diphosphate, collectively referred to as (p)ppGpp] synthesized by the transfer of pyrophosphate from ATP to the 3′ position of the ribose of GDP or GTP (Haseltine et al., 1972 ▸). An increased concentration of the alarmone drives the so-called stringent response, a crucial mechanism of bacterial adaptation to a rapidly and continuously changing environment (Laffler & Gallant, 1974 ▸). The stringent response affects transcription, translation and DNA replication (Durfee et al., 2008 ▸; Mechold et al., 2013 ▸). The effects of (p)ppGpp on gene expression are mediated via direct binding to its molecular targets, RNA polymerase, DnaG and translational GTPases (Ross et al., 2013 ▸; Zuo et al., 2013 ▸), or indirectly by the depletion of GTP from the available nucleotide pool (Geiger et al., 2014 ▸; Krásný & Gourse, 2004 ▸). Induction of the stringent response leads to growth arrest and is involved in virulence and biofilm formation (Hauryliuk et al., 2015 ▸; Liu et al., 2015 ▸).
The RSH (RelA/SpoT homologues) enzymes synthesize and degrade (p)ppGpp to control its concentration in the cell (Stent & Brenner, 1961 ▸). This protein superfamily is named after the Escherichia coli relA and spoT genes, which were discovered as a set of factors that control the synthesis of so-called stable RNA: rRNA and tRNA (Stent & Brenner, 1961 ▸). The RSH family consists of three subfamilies of enzymes that differ mainly in domain content and catalytic activity (Atkinson et al., 2011 ▸). The ribosome-associated long RSH subfamily includes the Rel enzymes (with bifunctional ppGpp synthetase and hydrolase activities), specialized ppGpp synthetases, such as RelA enzymes, that have lost their hydrolase activity, and the specialized SpoT ppGpp hydrolase enzymes that have retained only poor synthetase activity. While the vast majority of bacteria encode one long bifunctional Rel, a gene-duplication event in β- and γ-proteobacteria resulted in divergence into the two more specialized enzyme homologues RelA and SpoT (Atkinson et al., 2011 ▸). The N-terminal region of long RSHs contains the two catalytic domains [the (p)ppGpp hydrolase (HD) domain and the (p)ppGpp synthetase (SYN) domain] and the C-terminal half is involved in regulation of the enzyme [Fig. 1 ▸(a)]. In addition, the superfamily includes small alarmone synthetase (SAS) homologues that consist only of the ppGpp catalytic domain and small alarmone hydrolase (SAH) homologues containing only the hydrolase catalytic domain. Both SASs and SAHs are stripped of the conserved C-terminal regulatory domains.
Figure 1.
Biochemical and biophysical characterization of RelTt and RelTt NTD. (a) Domain composition of long RSH enzymes and structural model based on the structure of E. coli RelA in the ribosome-bound state (PDB entry 5l3p; Arenz et al., 2016 ▸). (b) Analytical SEC of RelTt (dark blue) and RelTt NTD (light blue) on a Superdex 200 Increase SEC column; the measurements were performed in 50 mM Tris pH 7.5, 500 mM NaCl, 500 mM KCl, 10 mM MgCl2, 1 mM TCEP, 0.002% mellitic acid. Estimation of the molecular weights of the proteins based on the SEC profiles suggest that they are both monomers in solution under these conditions. (c) Stability of RelTt NTD in the absence (orange) and presence (green) of mellitic acid monitored by thermal shift assay. (d) Stability of RelTt NTD in the presence (blue) and absence (red) of Mn2+ monitored by thermal shift assay. Removal of the metal ion decreases the T m of the enzyme by 3°C. (e) Binding of Mn2+ to metal-free RelTt NTD monitored by isothermal titration calorimetry (K d = 420 nM). The binding is largely enthalpically driven (ΔH = 3.5 kcal mol−1), suggesting that the Mn2+ coordination involves structuring of the HD domain. (f) TLC showing the ppGpp hydrolase activity of RelTt in the presence of 32P-labelled ppGpp (lane 1 shows the migration of the control 32ppGpp) either at 40°C (lane 2) or 4°C (lane 3). The migration of ppGpp and pyrophosphate (PP) is shown in red. (g) ppGpp synthetase activity of RelTt in the presence of 100 µM cold ppGpp as activator, 1 mM APPNP or 1 mM ATP and 0.3 mM 3H-labelled GDP.
High-resolution structural information on long RSHs is limited to the structure of the N-terminal region of Streptococcus dysgalactiae subsp. equisimilis Rel (RelSeq NTD), which contains the two opposing catalytic domains of the enzyme (Hogg et al., 2004 ▸). RelSeq is a bona fide bifunctional enzyme, and interestingly the structure of RelSeq NTD contained two distinct conformations in the same crystal lattice that underscore the antagonistic functions of the enzyme. However, it failed to fully capture the regulatory mechanism, including the changes required for the incorporation of ATP into the active site of the synthetase domain (Hogg et al., 2004 ▸). Nevertheless, the conformational changes observed in the crystal structure suggested that a nucleotide-triggered swinging motion of the synthetase domain could be involved in the switch from one activity to the other. Further insights into the catalytic mechanism of RSHs came from the structures of the SASs RelP and RelQ that revealed the key catalytic residues of the synthetase domain and how ATP and GTP are engaged in the active site in a pre-catalytic state (Manav et al., 2018 ▸; Steinchen et al., 2015 ▸).
More nuanced regulatory mechanisms of RSH enzymes that control the enzymatic output by sensing the physiological state of the cell involve the interactions of cellular partners via the C-terminal regulatory domains (Gully et al., 2003 ▸; Ramagopal & Davis, 1974 ▸; Ronneau et al., 2019 ▸), including ‘starved’ ribosomal complexes containing deacylated tRNA in the A-site (Loveland et al., 2016 ▸; Brown et al., 2016 ▸; Arenz et al., 2016 ▸), the acyl-carrier protein (ACP; Gully et al., 2003 ▸) and the PtsN phosphorelay (Ronneau et al., 2019 ▸). In addition, (p)ppGpp itself controls E. coli RelA via positive allosteric feedback regulation (Shyp et al., 2012 ▸).
Here, we describe the purification and the structure determination by X-ray crystallography of three different crystal forms of the catalytic domain of a bifunctional Rel RSH enzyme from Thermus thermophilus.
2. Materials and methods
2.1. Cloning
The chemically synthesized rel gene from T. thermophilus (rel Tt) was cleaved with the NdeI and XhoI restriction enzymes (NEB) and transferred to pET-21b, which was cut with the same restriction enzymes and dephosphorylated with alkaline phosphatase (NEB). The sequence of the resulting plasmid, pET-21b-HisTEV-RelTt, was verified by sequencing (Eurofins Genomics). To acquire a plasmid for the overexpression of solely the catalytic (N-terminal) domain of the RelTt protein (RelTt NTD), the C-terminal part of the gene (from Val356) was removed by amplifying the plasmid with primers (Sigma–Aldrich) flanking the sequence to be deleted (Table 1 ▸) using Q5 High-Fidelity Polymerase (Sigma–Aldrich). The acquired PCR reaction mixtures were treated with DpnI (NEB) to remove the pET-21b-HisTEV-RelTt plasmid used as the template (see Table 2 ▸ for the full sequence of each protein variant). Finally, the PCR products were purified using a PCR purification column (Sigma), phosphorylated with PNK (Sigma) and ligated. The ligation mixture was transferred into E. coli strain MC1061 by electroporation. The resulting plasmid pET-21b-HisTEV-RelTt NTD (residues 1–355; Table 2 ▸) was then purified and its sequence was confirmed by standard sequencing methods (Eurofins Genomics).
Table 1. Sequences of the recombinant proteins used in this work.
| Name | Sequence |
|---|---|
| His-TEV-RelTt | MGSSHHHHHHSSGENLYFQGASVGADLGLWNRLEPALAYLAPEERAKVREAYRFAEEAHRGQLRRSGEPYITHPVAVAEILAGLQMDADTVAAGLLHDTLEDCGVAPEELERRFGPTVRRIVEGETKVSKLYKLANLEGEERRAEDLRQMFIAMAEDVRIIIVKLADRLHNLRTLEHMPPEKQKRIAQETLEIYAPLAHRLGMGQLKWELEDLSFRYLHPEAFASLSARIQATQEARERLIQKAIHLLQETLARDELLQSQLQGFEVTGRPKHLYSIWKKMEREGKTLEQIYDLLAVRVILDPKPAPTRESQALREKQVCYHVLGLVHALWQPIPGRVKDYIAVPKPNGYQSLHTTVIALEGLPLEVQIRTREMHRVAEYGIAAHWLYKEGLTDPEEVKRRVSWLKSIQEWQKEFSSSREFVEAVTKDLLGGRVFVFTPKGRIINLPKGATPVDFAYHIHTEVGHHMVGAKVNGRIVPLSYELQNGEIVEILTSKNAHPSKGWLEFAKTRSAKSKIRQYFRAQERQETLEKGQHLLERYLKRRGLPKPTDSQLEEAAKRLSLPPSPEELYLALALNRLTPRQVAEKLYPKALLKPEKPKPQARNEWGIRLEQDLQAPIRLASCCEPMKGDPILGFVTRGRGVTVHRADCPNLRRLLQGPEADRVIGAYWEGVGGKVVVLEVLAQDRAGLLRDVMQVVAEAGKSALGSETRVLGPLARIRLRLAVQDGEEERILQAVQKVSGVKEARWA |
| His-TEV-RelTt NTD | MGSSHHHHHHSSGENLYFQGASVGADLGLWNRLEPALAYLAPEERAKVREAYRFAEEAHRGQLRRSGEPYITHPVAVAEILAGLQMDADTVAAGLLHDTLEDCGVAPEELERRFGPTVRRIVEGETKVSKLYKLANLEGEERRAEDLRQMFIAMAEDVRIIIVKLADRLHNLRTLEHMPPEKQKRIAQETLEIYAPLAHRLGMGQLKWELEDLSFRYLHPEAFASLSARIQATQEARERLIQKAIHLLQETLARDELLQSQLQGFEVTGRPKHLYSIWKKMEREGKTLEQIYDLLAVRVILDPKPAPTRESQALREKQVCYHVLGLVHALWQPIPGRVKDYIAVPKPNGYQSLHTTVIALEGLPLEVQIRTREMHR |
Table 2. Crystallization conditions observed for RelTt NTD .
Conditions shown in bold yielded the crystals that were used for data collection.
| Enzyme | Condition | Temperature (K) | Cryoprotectant |
|---|---|---|---|
| RelTt NTD | Morpheus II B11 | 20 | — |
| RelTt NTD | Morpheus II C10 | 20 | — |
| RelTt NTD | Morpheus II C11 | 20 | — |
| RelTt NTD | Morpheus II E10 | 20 | — |
| RelTt NTD | Morpheus II F10 | 20 | — |
| RelTt NTD | Morpheus II G6 | 20 | — |
| RelTt NTD | Morpheus II G10 | 20 | — |
| RelTt NTD | Morpheus II H11 | 20 | — |
| RelTt NTD | PACT premier E4 | 20 | PEG 400 |
| RelTtNTD | PACT premier G2 | 20 | PEG 400 |
| RelTt NTD | PACT premier G3 | 20 | 25% MPD, 20% glycerol, 1 M TMAO |
| RelTt NTD | PACT premier H4 | 20 | 20% glycerol |
| RelTtNTD + APPNP | PACT premier D12 | 20 | 3 M TMAO |
| RelTt NTD + APPNP | PACT premier G5 | 20 | 3 M TMAO, 20% glycerol, PEG 400 |
| RelTt NTD + APPNP | PACT premier G10 | 20 | 1.5 M TMAO, 20% glycerol, 50 mM APPNP, 50 mM GDP, PEG 400 |
| RelTt NTD + GDP | Morpheus II G5 | 20 | — |
| RelTt NTD + GDP | Morpheus II G6 | 20 | — |
| RelTtNTD | Morpheus II G8 | 4 | — |
2.2. Protein expression and preparation for purification
RelTt or its catalytic domain RelTt NTD with an N-terminal His6 tag and a TEV protease recognition site were expressed from the plasmids pET-21b-HisTEV-RelTt and pET-21b-HisTEV-RelTt NTD, respectively. The plasmids were transferred into E. coli BL21(DE3) cells by electroporation. The cells carrying the plasmid were grown to an OD600 of 0.6 at 37°C in LB supplemented with ampicillin (100 mg l−1) prior to induction of protein expression by the addition of IPTG (final concentration of 0.5 mM) at 28°C. Expression took place for 5 h for RelTt NTD or overnight for RelTt. Next, the cells were collected and resuspended in resuspension buffer (50 mM Tris–HCl pH 8, 1.5 M KCl, 2 mM MgCl2, 1 mM TCEP) supplemented with cOmplete protease-inhibitor cocktail (Roche). If not used immediately for downstream applications, the cells were flash-frozen in liquid nitrogen and stored at −80°C.
The cell extracts were prepared using a cell cracker equilibrated with lysis buffer (50 mM Tris–HCl pH 8, 500 mM NaCl, 500 mM KCl, 1 mM TCEP) supplemented with cOmplete protease-inhibitor cocktail (Roche). The pellet was separated from the supernatant by centrifugation for 30 min at 25 000g.
2.3. Protein purification and preparation for crystallization
The supernatant was loaded onto a gravity-flow TALON column previously equilibrated with buffer A (25 mM Tris pH 8, 500 mM NaCl, 500 mM KCl, 10 mM MgCl2, 0.002% mellitic acid). The column was washed with seven column volumes of buffer A and the bound protein was eluted stepwise with buffers B1–B3 (buffer A containing 50, 125 and 500 mM imidazole, respectively). The elution fractions containing His-RelTt NTD were immediately concentrated using spin filters (Amicon) and loaded onto a GE Healthcare Superdex 200 16/60 gel-filtration column equilibrated with GF buffer (50 mM Tris pH 8, 500 mM NaCl, 500 mM KCl, 10 mM MgCl2, 0.002% mellitic acid). The purity of the protein fractions was assessed by SDS–PAGE. The pure protein was immediately used for further applications or stored in 35% glycerol at −20°C for up to one week.
The His tag was cleaved off from the His-TEV-RelTt NTD protein by adding TEV protease in a 1:100 molar ratio and incubating overnight at room temperature. The quality of the protein samples post-cleavage was then analysed by SDS–PAGE. Complete removal of the tag was confirmed by Western blotting using an anti-poly-His antibody (Sigma; catalogue No. H1029). To separate RelTt NTD from the His-tagged protease and free poly-His tag, the mixture was passed through a TALON column. The cleaved protein was subsequently concentrated to 10–12 mg ml−1 for crystallization.
2.4. Preparation of metal-free RelTt NTD
Metal-free RelTt NTD (10 µM) was prepared as described for other Mn2+-binding proteins (Garcia-Pino et al., 2006 ▸) with minor modifications. Briefly, the enzyme was dialysed at 8°C into 50 mM HEPES pH 7.5, 500 mM KCl, 500 mM NaCl, 1 mM TCEP, 0.002% mellitic acid, 100 mM EDTA to remove the Mn2+ ion bound to RelTt NTD. For the dialysis we used 12–14 kDa cutoff dialysis membranes (SpectrumLabs) and incubated the sample for 1 h, after which the buffer was exchanged and dialysis was continued overnight. After dialysis, the buffer was exchanged to the isothermal titration calorimetry buffer (50 mM HEPES pH 7.5, 500 mM KCl, 500 mM NaCl, 1 mM TCEP, 0.002% mellitic acid) by size-exclusion chromatography on a Superdex 200 column (GE Healthcare).
2.5. Isothermal titration calorimetry
For the ITC titrations, the Mn2+-free RelTt NTD was concentrated to around 50 µM using ultrafiltration units (Amicon). The MnCl2 (Merck) used to titrate RelTt NTD was dissolved in a matching buffer to a concentration of 400–1000 µM. The titrations were performed on an affinity ITC instrument (TA Instruments) at 10°C by injecting 2 µl of the MnCl2 solution for each titration point at 200 s intervals with the stirring rate set to 75 rev min−1. Data analysis and modelling were performed as described previously (Garcia-Pino et al., 2016 ▸; Talavera et al., 2018 ▸) with NanoAnalyze (TA Instruments) and MicroCal Origin 7.0.
2.6. ppGpp synthesis and hydrolysis assays
H3-ppGpp synthesis assays were performed as described for E. coli RelA (Kudrin et al., 2018 ▸) with minor modifications. The reaction mixtures typically contained 120 nM T. thermophilus 70S IC (MV), 30 nM RelTt, guanosine nucleotide substrate (300 µM H3-GDP, PerkinElmer), ppGpp 100 µM and 2 µM E. coli tRNAVal, all in HEPES:Polymix buffer at a final Mg2+ concentration of 5 mM. After pre-incubation at 40°C for 3 min, the reaction was started by the addition of preheated ATP or APPNP {adenosine 5′-[(β,γ)-imido]triphosphate} to a final concentration of 1 mM and quenched with 4 µl 70% formic acid supplemented with a cold nucleotide standard (4 mM GDP) for UV-shadowing. Individual quenched time points were spotted onto PEI-TLC plates (Macherey-Nagel) and the nucleotides were resolved in 0.5 M KH2PO4 pH 3.5 buffer. 3H radioactivity was quantified by scintillation counting in an Optisafe-3 (Fisher Scientific) scintillation cocktail.
For 32ppGpp hydrolysis assays, 32P-labelled ppGpp was synthesized by incubating Rel from Chlorobaculum tepidum with 1 mM GDP and 3 nM ATP-[γ-32P] (PerkinElmer) for 90 min. Hydrolysis assays were performed in 20 µl reactions with 1 µM RelTt and 1.5 nM 32ppGpp in reaction buffer: 1 mM MgCl2, 1 mM TCEP, 10 mM Tris pH 7.4, 50 mM NaCl. The reaction mixtures were incubated at 4 or 40°C for 20 min and quenched by the addition of 2 µl formic acid (Sigma–Aldrich). 2 µl of each mixture was spotted onto a PEI-Cellulose F TLC plate (Merck Millipore) and resolved in 1 M KH2PO4 at pH 3. The dried TLC plates were exposed to a BAS storage phosphor screen (GE Healthcare) for 1 h. The storage screen was scanned with an Amersham Typhoon Phosphorimager (GE Healthcare).
2.7. Thermal shift assay
Thermal shift assays were performed on 25 µl mixtures that consisted of 2.5 µl RelTt NTD (100 µM) and 2.5 µl of a 100× dilution (in water) of SYPRO Orange 5000× concentrate (ThermoFisher). The final volume was achieved with 16 µl TF buffer (50 mM HEPES pH 7.5, 500 mM KCl, 500 mM NaCl, 1 mM TCEP, 0.002% mellitic acid) and 4 µl 100 mM EDTA when testing the stabilizing effect of Mn2+ on RelTt NTD and with 20 µl TF buffer with (0.002%) or without mellitic acid to test the stabilizing effect of mellitic acid. The experiment was set up in 96-well real-time PCR plates and the fluorescence of the solutions was measured at 490 nm excitation and 550 nm emission in real-time PCR instruments (Bio-Rad C1000 Thermal cycler for EDTA experiments and Applied Biosystems StepOnePlus for the mellitic acid experiment), increasing the temperature of the wells by 1°C min−1 from 15 to 95°C.
2.8. Crystallization
Crystallization conditions were screened at 20 and 4°C by the sitting-drop vapour-diffusion method. The drops were set up in Swissci (MRC) 96-well 2-drop UVP sitting-drop plates using a Mosquito robotic system (TTP Labtech). Drops consisting of 0.1 µl protein solution and 0.1 µl precipitant solution were equilibrated against 80 µl precipitant solution in the reservoir. Crystallization conditions were tested with several commercially available screens: Crystal Screen, Crystal Screen 2 (Hampton Research), Helix, ProPlex, PACT premier, JCSG-plus, The LMB Crystallization Screen and Morpheus II (Molecular Dimensions). The concentrations of the protein solutions were determined from the absorbance at 280 nm and were corrected by theoretical extinction coefficients calculated using ProtParam (Gasteiger et al., 2003 ▸).
For the co-crystallization of RelTt NTD with nucleotides, 12 mg ml−1 RelTt NTD was mixed with nucleotides at 50 mM or 100 mM and incubated for 10 min at room temperature. The commercially available screens Morpheus II, PACT premier and SG1 (Molecular Dimensions) were used to screen for crystallization conditions using a Mosquito HTS robot.
2.9. Data collection and processing
Prior to data collection, all crystals were vitrified in liquid N2 after cryoprotection (see Table 2 ▸ for details of the cryoprotective solutions that were used). In the case of co-crystals with nucleotides, the cryoprotective solution included the nucleotides at 20 mM. X-ray diffraction data were collected on the PROXIMA 1 (PX1) and PROXIMA 2A (PX2A) beamlines at the SOLEIL Synchrotron, Gif-sur-Yvette, Paris, France. All data were indexed, integrated with XDS and scaled with XSCALE (Kabsch, 2010 ▸) or AIMLESS (Evans, 2006 ▸). Data quality and twinning were assessed with phenix.xtriage (Afonine et al., 2012 ▸), and POINTLESS (Evans, 2006 ▸) was used for determination of the space group.
2.10. Structure solution
Data were collected from vitrified crystals of RelTt NTD at 100 K. MATTHEWS_COEF was used to calculate Matthews coefficients for cell-content analysis (Winn et al., 2011 ▸). Self-rotation functions were calculated with MOLREP (Murshudov et al., 2011 ▸) and molecular replacement was performed with Phaser (McCoy et al., 2007 ▸) using the coordinates of RelSeq NTD (PDB entry 1vj7) as an initial search model (Hogg et al., 2004 ▸). Automated model building of the data set collected at 4°C was performed with ARP/wARP (Langer et al., 2008 ▸).
3. Results and discussion
3.1. Purification of RelTt and RelTt NTD
For the purification of RelTt, we used a gravity-flow column filled with 1 ml TALON resin followed by size-exclusion chromatography (SEC), as shown in Fig. 1 ▸(b). RelTt elutes at approximately 14.0 ml from a Superdex Increase 200 13/30 column (GE Healthcare), corresponding to a size of approximately 95 kDa, which is of the order of the molecular weight expected for a RelTt monomer. For biochemical assays, the enzyme underwent an additional desalting step using a Hi-Prep 26/10 desalting column to remove potential nonspecific RNA contaminants, followed by another SEC step, and only samples with a ratio of absorption at 260 nm/280 nm of between 0.6 and 0.7 were used in further experiments. After purification by SEC, both versions of the protein were concentrated to 10–12 mg ml−1 and used to screen for crystallization conditions.
Long Rel enzymes are notoriously difficult to study because of their poor stability and their tendency to oligomerize. Therefore, we also focused on the crystallization of the N-terminal catalytic domains of RelTt (RelTt NTD) to study the allosteric control of the different substrates of the enzyme on its conformational landscape. RelTt NTD included residues 1–355 preceded by an N-terminal His tag and a TEV cleavage sequence. RelTt NTD was purified using the same strategy as described for RelTt. Analytical SEC performed on a Superdex Increase 200 13/30 column (GE Healthcare) after the initial affinity chromatography step showed that RelTt NTD elutes at approximately 16.0 ml, which is consistent with a monomeric species [Fig. 1 ▸(b)]. After removing the His tag and additional SEC, RelTt NTD was concentrated for crystallization.
3.2. RelTt is stabilized by mellitic acid
To further stabilize RelTt, we used the Silver Bullets screen from Hampton Research to screen for compounds that would increase the melting temperature of RelTt as monitored by a thermal shift assay. The screen contains a varied collection of metal ions and organic compounds that could bind and stabilize the enzyme and increase its chances of crystallization. This screening highlighted mellitic acid as a compound that increases the T m of RelTt NTD by between 1.5 and 2°C at concentrations of between 0.002% and 0.02% [Fig. 1 ▸(c)]. Therefore, we decided to include mellitic acid at 0.002% in all of the purification steps of RelTt and RelTt NTD prior to crystallization. This allowed us to concentrate the enzyme to above 10 mg ml−1.
3.3. Biochemical and biophysical characterization of RelTt
The N-terminal region of long Rel enzymes harbours two catalytic domains with opposing activities. In RelTt NTD the HD domain (residues 1–158) has a pyrophospho-hydrolase activity and is involved in the cellular degradation of (p)ppGpp, whereas the SYN domain (residues 198–355) binds GTP/GDP and ATP to synthesize (p)ppGpp. It has long been speculated that the nucleotide substrates of the enzyme dictate the conformational arrangement of the domains in the NTD region based on the structures of RelSeq NTD. However, these structures failed to capture the full regulatory mechanism that involves allosteric triggering of metal ion-catalysed hydrolysis and a strong protein-dynamics component.
Therefore, we decided to characterize the interaction of RelTt NTD with Mn2+ (the metal ion bound in the HD domain) and its substrates, as well as the effect of temperature on catalysis, to guide the crystallization process. The presence of Mn2+ seems to stabilize the enzyme based on a decrease in the T m of 3°C observed after incubating the enzyme with EDTA to remove the Mn2+ ion [Fig. 1 ▸(d)]. Isothermal titration calorimetry (ITC) shows that the enzyme binds Mn2+ with an affinity of 420 nM [Fig. 1 ▸(e)]. The observed K d is lower than expected based on earlier observations for other Rel enzymes (Avarbock et al., 2005 ▸). However, it is in agreement with the cellular concentration of Mn2+ in bacterial cells which is in the µM range (Foster et al., 2014 ▸). In addition, temperature also has a strong effect on catalysis, precluding ppGpp hydrolysis at 4°C [Fig. 1 ▸(f)].
The synthesis of ppGpp involves the pyrophosphorolysis of the α–β phosphoric anhydride bond of ATP. Therefore, we reasoned that substituting the O atom of the adjacent β–γ phosphoric anhydride bond could impact the catalytic reaction, facilitating structural studies of the catalytic mechanism. Indeed, using APPNP (an analogue of ATP in which the β–γ oxygen is substituted by an NH group) instead of ATP slows the reaction by around 50-fold [Fig. 1 ▸(g)]. Based on these results, we decided to pursue the crystallization of RelTt NTD at low temperatures and in the presence of APPNP (besides the obvious natural substrates and real nonhydrolysable substrates such as APCPP) to increase the chance of obtaining catalytically meaningful conformations.
3.4. Preliminary X-ray analysis of the RelTt NTD crystals
RelTt NTD crystallized in various conditions, resulting in crystals with various morphologies and size distributions [Figs. 2 ▸(a)–2 ▸(c)]. These crystals diffracted to around 10 Å resolution on average; however, a series of changes of the sodium salt used during crystallization regularly improved the resolution of the diffraction pattern to around 2.8 Å. The addition of nucleotides to RelTt NTD also resulted in new crystallization conditions, with hits obtained using different nucleotide combinations, and nucleotides were also included in the cryoprotective solutions to soak the crystals of RelTt NTD prior to vitrification in liquid N2 (Table 2 ▸). Temperature was also a crucial factor in improving the quality of the diffraction pattern. The best diffracting crystals in terms of resolution and lower anisotropic features were obtained with crystals grown at 4°C.
Figure 2.
Typical crystals of RelTt NTD grown under different conditions. Crystals of RelTt NTD in the presence of APPNP at 20°C (a) and of RelTt NTD at 20°C (b) and at 4°C (c).
These crystals of RelTt NTD obtained at 4°C were around 70 µm along the largest direction on average and grew after two weeks of incubation. These crystals diffracted to 2.7 Å resolution (Table 3 ▸) and belonged to space group P4122 (or P4322). Based on the unit-cell content analysis, there could be one or two molecules in the asymmetric unit (with a solvent content of 70% or 40% based on Matthews coefficients of 4.1 and 2.0 Å3 Da−1, respectively). However, analysis of the self-rotation function is consistent with only one molecule in the asymmetric unit, with only trivial peaks observed in the κ = 180° section of the self-rotation function corresponding to the crystallographic twofold [Fig. 3 ▸(a)]. An initial search using each of the two conformations of RelSeq NTD (PDB entry 1vj7) failed to deliver a conclusive molecular-replacement solution. RelTt NTD and RelSeq NTD have an overall sequence identity of 40%, with the HD domain having a local sequence identity of 47% and the SYN domain having an identity of around 40%. Considering that the enzyme is also notoriously dynamic, we decided to search using ensembles generated from each individual RelSeq NTD domain. Using this approach, we obtained a molecular-replacement solution with Phaser in space group P4122 consistent with one molecule in the asymmetric unit, with a final TFZ of 30.1, PAK = 1 and LLG = 650. This solution is significantly better than that in the alternate space group P4322, with a TFZ of 12.3, PAK = 4 and LLG = 145, which confirmed P4122 as the correct space group. We then used ARP/wARP for automated model building starting from this molecular-replacement solution and were able to reconstruct 80% of the backbone [Fig. 3 ▸(b)].
Table 3. Data collection and processing.
The CC1/2 criterion was used to determine the resolution range. Values in parentheses are for the outer shell.
| RelTt NTD (4°C) | RelTt NTD (20°C) | RelTt NTD–GDP–APPNP (20°C) | |
|---|---|---|---|
| Diffraction source | PX1, SOLEIL | PX1, SOLEIL | PX2A, SOLEIL |
| Wavelength (Å) | 1.008 | 0.9786 | 0.9801 |
| Temperature (K) | 100 | 100 | 100 |
| Detector | PILATUS 6M | PILATUS 6M | EIGER |
| Crystal-to-detector distance (mm) | 582.01 | 623.60 | 342.51 |
| Rotation range per image (°) | 0.1 | 0.1 | 0.1 |
| Total rotation range (°) | 190 | 200 | 360 |
| Exposure time per image (s) | 0.1 | 0.1 | 0.1 |
| Space group | P4122 | P41212 | C2 |
| a, b, c (Å) | 88.4, 88.4, 182.7 | 105.7, 105.7, 241.4 | 120.8, 50.3, 86.1 |
| α, β, γ (°) | 90.0, 90.0, 90.0 | 90.0, 90.0, 90.0 | 90.0, 111.0, 90.0 |
| Mosaicity (°) | 0.07 | 0.07 | 0.21 |
| Resolution range (Å) | 51.60–2.75 (2.85–2.75) | 240.00–2.90 (2.94–2.90) | 56.36–2.95 (3.06–2.95) |
| Total No. of reflections | 156684 (2496) | 297021 (487) | 67782 (2399) |
| No. of unique reflections | 12385 (223) | 21377 (50) | 6572 (255) |
| Completeness after anisotropic correction (%) | 94.7 (97.9) | 93.7 (90.9) | 91.9 (94.8) |
| Multiplicity | 12.7 (11.2) | 13.9 (9.7) | 10.3 (9.4) |
| 〈I/σ(I)〉 | 10.2 (1.2) | 14.4 (1.2) | 13.8 (2.2) |
| CC1/2 | 1.00 (0.61) | 1.00 (0.45) | 1.00 (0.87) |
| R r.i.m. | 0.21 (1.69) | 0.12 (1.70) | 0.12 (1.1) |
| R p.i.m. | 0.06 (0.52) | 0.05 (0.75) | 0.04 (0.36) |
| Overall B factor from Wilson plot (Å2) | 47.95 | 105.42 | 79.99 |
Figure 3.
Preliminary X-ray analysis of the RelTt NTD crystals. (a) Self-rotation function at the κ = 180° section of the data collected from the RelTt NTD crystals grown at 4°C, consistent with only one molecule in the asymmetric unit. (b) Initial 2mF o − DF c map (σ = 1.5) for the RelTt NTD crystals grown at 4°C after automated model building with ARP/wARP. The autotraced Cα backbone is shown in red. Self-rotation function at the κ = 180° section (c) and κ = 120° section (d) of the data collected from the RelTt NTD crystals grown at 20 °C.
In addition, we grew crystals of RelTt NTD at 20°C that were around 100 µm in size on average and appeared within a week of incubation. These crystals diffracted to 2.8 Å resolution on average (Table 3 ▸) and belonged to space group P41212 (or P43212). However, these crystals were very anisotropic, with the magnitude of the anisotropy expressed as a function of the resolution along the h, k and l axes estimated as 2.5, 3.1 and 4.5 Å, respectively. Analysis of the unit-cell content of these crystals predicted that they contain three molecules of RelTt NTD (52% solvent content and a Matthews coefficient of 2.65 Å3 Da−1). The self-rotation function of these RelTt NTD crystals had strong features at χ values of 180° and 120° consistent with three molecules in the asymmetric unit, in agreement with the cell-content analysis [Figs. 3 ▸(c) and 3 ▸(d)]. Indeed, using the individual HD and SYN domains of RelSeq NTD (PDB entry 1vj7) as a search model, Phaser found the equivalent of three molecules in the asymmetric unit in space group P41212, with a final TFZ of 17.2, PAK = 2 and LLG = 1151. This solution was of considerably higher quality than that of the alternate space group P43212 (TFZ of 10.9, PAK = 6 and LLG = 28) to conclusively assign P41212 as the correct space group.
We also took advantage of the aforementioned slower reaction of RelTt NTD involving APPNP for crystallization. This resulted in crystals of a C2 form of RelTt NTD that were around 200 µm in size on average and typically appeared within a week after setting up the drops. These crystals were typically very anisotropic, diffracting on average to a resolution of around 2.9 Å in the best direction (Table 3 ▸), with the anisotropy expressed as a function of the resolution along the h, k and l axes estimated as 3.4, 3.4 and 2.9 Å, respectively. For data collection the cryoprotective solution was supplemented with 50 mM APPNP and 50 mM GDP and was incubated for 5–10 min before vitrification. Analysis of the unit-cell content suggested that there was only one molecule in the asymmetric unit based on a Matthews coefficient of 2.77 Å3 Da−1, which corresponds to a solvent content of 55.7%. Molecular replacement with Phaser, using ensembles of HD and SYN domains generated from the structure of RelSeq NTD as search models, found a solution in space group C2 that was consistent with one molecule in the asymmetric unit, with a final TFZ of 26.7, PAK = 0 and LLG = 1185. Structure refinement and completion is ongoing in all cases.
4. Conclusions
Long Rel stringent factors are the most broadly distributed class of RSHs. This family of enzymes regulate the synthesis and hydrolysis of the bacterial alarmone (p)ppGpp, which is the key factor in the stringent response. The structural basis of the regulation of Rel is not completely understood, in particular the role of nucleotides in the allosteric triggering of the opposing catalytic activities. Because of its intrinsic stability, we used T. thermophilus Rel as a model system to study this nucleotide-based allosteric control and obtained crystals of the catalytic region of the enzyme in different conditions and in the presence and absence of nucleotides. The corresponding crystal structures are likely to enhance our understanding of the function and regulation of the catalytic activity of Rel enzymes by their nucleotide substrates.
Acknowledgments
We acknowledge the use of the synchrotron-radiation facility at the SOLEIL synchrotron, Gif-sur-Yvette, France under proposals 20150717, 20160750 and 20170756; we also thank the staff of the PROXIMA 1 and PROXIMA 2A beamlines at SOLEIL for assistance with data collection.
Funding Statement
This work was funded by Fonds De La Recherche Scientifique - FNRS grants FNRS-EQP U.N043.17F,, FRFS-WELBIO CR-2017S-03, FNRS-PDR T.0066.18, and CR/DM-392. Université Libre de Bruxelles grant . Fonds Jean Brachet grant . Fonds Alice et David van Buuren grant . Umeå Centre for Microbial Research grant . Molecular Infection Medicine Sweden grant . Vetenskapsrådet grant .
References
- Afonine, P. V., Grosse-Kunstleve, R. W., Echols, N., Headd, J. J., Moriarty, N. W., Mustyakimov, M., Terwilliger, T. C., Urzhumtsev, A., Zwart, P. H. & Adams, P. D. (2012). Acta Cryst. D68, 352–367. [DOI] [PMC free article] [PubMed]
- Arenz, S., Abdelshahid, M., Sohmen, D., Payoe, R., Starosta, A. L., Berninghausen, O., Hauryliuk, V., Beckmann, R. & Wilson, D. N. (2016). Nucleic Acids Res. 44, 6471–6481. [DOI] [PMC free article] [PubMed]
- Atkinson, G. C., Tenson, T. & Hauryliuk, V. (2011). PLoS One, 6, e23479. [DOI] [PMC free article] [PubMed]
- Avarbock, A., Avarbock, D., Teh, J.-S., Buckstein, M., Wang, Z.-M. & Rubin, H. (2005). Biochemistry, 44, 9913–9923. [DOI] [PubMed]
- Brown, A., Fernández, I. S., Gordiyenko, Y. & Ramakrishnan, V. (2016). Nature (London), 534, 277–280. [DOI] [PMC free article] [PubMed]
- Durfee, T., Hansen, A. M., Zhi, H., Blattner, F. R. & Jin, D. J. (2008). J. Bacteriol. 190, 1084–1096. [DOI] [PMC free article] [PubMed]
- Evans, P. (2006). Acta Cryst. D62, 72–82. [DOI] [PubMed]
- Foster, A. W., Osman, D. & Robinson, N. J. (2014). J. Biol. Chem. 289, 28095–28103. [DOI] [PMC free article] [PubMed]
- Garcia-Pino, A., Buts, L., Wyns, L. & Loris, R. (2006). J. Mol. Biol. 361, 153–167. [DOI] [PubMed]
- Garcia-Pino, A., De Gieter, S., Talavera, A., De Greve, H., Efremov, R. G. & Loris, R. (2016). Nature Chem. Biol. 12, 490–496. [DOI] [PubMed]
- Gasteiger, E., Gattiker, A., Hoogland, C., Ivanyi, I., Appel, R. D. & Bairoch, A. (2003). Nucleic Acids Res. 31, 3784–3788. [DOI] [PMC free article] [PubMed]
- Geiger, T., Kästle, B., Gratani, F. L., Goerke, C. & Wolz, C. (2014). J. Bacteriol. 196, 894–902. [DOI] [PMC free article] [PubMed]
- Gully, D., Moinier, D., Loiseau, L. & Bouveret, E. (2003). FEBS Lett. 548, 90–96. [DOI] [PubMed]
- Haseltine, W. A., Block, R., Gilbert, W. & Weber, K. (1972). Nature (London), 238, 381–384. [DOI] [PubMed]
- Hauryliuk, V., Atkinson, G. C., Murakami, K. S., Tenson, T. & Gerdes, K. (2015). Nature Rev. Microbiol. 13, 298–309. [DOI] [PMC free article] [PubMed]
- Hogg, T., Mechold, U., Malke, H., Cashel, M. & Hilgenfeld, R. (2004). Cell, 117, 57–68. [DOI] [PubMed]
- Kabsch, W. (2010). Acta Cryst. D66, 125–132. [DOI] [PMC free article] [PubMed]
- Krásný, L. & Gourse, R. L. (2004). EMBO J. 23, 4473–4483. [DOI] [PMC free article] [PubMed]
- Kudrin, P., Dzhygyr, I., Ishiguro, K., Beljantseva, J., Maksimova, E., Oliveira, S. R. A., Varik, V., Payoe, R., Konevega, A. L., Tenson, T., Suzuki, T. & Hauryliuk, V. (2018). Nucleic Acids Res. 46, 1973–1983. [DOI] [PMC free article] [PubMed]
- Laffler, T. & Gallant, J. A. (1974). Cell, 3, 47–49. [DOI] [PubMed]
- Langer, G., Cohen, S. X., Lamzin, V. S. & Perrakis, A. (2008). Nature Protoc. 3, 1171–1179. [DOI] [PMC free article] [PubMed]
- Liu, K., Myers, A. R., Pisithkul, T., Claas, K. R., Satyshur, K. A., Amador-Noguez, D., Keck, J. L. & Wang, J. D. (2015). Mol. Cell, 57, 735–749. [DOI] [PMC free article] [PubMed]
- Loveland, A. B., Bah, E., Madireddy, R., Zhang, Y., Brilot, A. F., Grigorieff, N. & Korostelev, A. A. (2016). Elife, 5, e17029. [DOI] [PMC free article] [PubMed]
- Manav, M. C., Beljantseva, J., Bojer, M. S., Tenson, T., Ingmer, H., Hauryliuk, V. & Brodersen, D. E. (2018). J. Biol. Chem. 293, 3254–3264. [DOI] [PMC free article] [PubMed]
- McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C. & Read, R. J. (2007). J. Appl. Cryst. 40, 658–674. [DOI] [PMC free article] [PubMed]
- Mechold, U., Potrykus, K., Murphy, H., Murakami, K. S. & Cashel, M. (2013). Nucleic Acids Res. 41, 6175–6189. [DOI] [PMC free article] [PubMed]
- Murshudov, G. N., Skubák, P., Lebedev, A. A., Pannu, N. S., Steiner, R. A., Nicholls, R. A., Winn, M. D., Long, F. & Vagin, A. A. (2011). Acta Cryst. D67, 355–367. [DOI] [PMC free article] [PubMed]
- Ramagopal, S. & Davis, B. D. (1974). Proc. Natl Acad. Sci. USA, 71, 820–824. [DOI] [PMC free article] [PubMed]
- Ronneau, S., Caballero-Montes, J., Coppine, J., Mayard, A., Garcia-Pino, A. & Hallez, R. (2019). Nucleic Acids Res. 47, 843–854. [DOI] [PMC free article] [PubMed]
- Ross, W., Vrentas, C. E., Sanchez-Vazquez, P., Gaal, T. & Gourse, R. L. (2013). Mol. Cell, 50, 420–429. [DOI] [PMC free article] [PubMed]
- Shyp, V., Tankov, S., Ermakov, A., Kudrin, P., English, B. P., Ehrenberg, M., Tenson, T., Elf, J. & Hauryliuk, V. (2012). EMBO Rep. 13, 835–839. [DOI] [PMC free article] [PubMed]
- Steinchen, W., Schuhmacher, J. S., Altegoer, F., Fage, C. D., Srinivasan, V., Linne, U., Marahiel, M. A. & Bange, G. (2015). Proc. Natl Acad. Sci. USA, 112, 13348–13353. [DOI] [PMC free article] [PubMed]
- Stent, G. S. & Brenner, S. (1961). Proc. Natl Acad. Sci. USA, 47, 2005–2014. [DOI] [PMC free article] [PubMed]
- Talavera, A., Hendrix, J., Versées, W., Jurėnas, D., Van Nerom, K., Vandenberk, N., Kumar Singh, R., Konijnenberg, A., De Gieter, S., Castro-Roa, D., Barth, A., De Greve, H., Sobott, F., Hofkens, J., Zenkin, N., Loris, R. & Garcia-Pino, A. (2018). Sci. Adv. 4, eaap9714. [DOI] [PMC free article] [PubMed]
- Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G. W., McCoy, A., McNicholas, S. J., Murshudov, G. N., Pannu, N. S., Potterton, E. A., Powell, H. R., Read, R. J., Vagin, A. & Wilson, K. S. (2011). Acta Cryst. D67, 235–242. [DOI] [PMC free article] [PubMed]
- Zuo, Y., Wang, Y. & Steitz, T. A. (2013). Mol. Cell, 50, 430–436. [DOI] [PMC free article] [PubMed]



